EP3522891A4 - Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer - Google Patents
Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer Download PDFInfo
- Publication number
- EP3522891A4 EP3522891A4 EP17858740.8A EP17858740A EP3522891A4 EP 3522891 A4 EP3522891 A4 EP 3522891A4 EP 17858740 A EP17858740 A EP 17858740A EP 3522891 A4 EP3522891 A4 EP 3522891A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- inhibitor
- treatment
- histone deacetylase
- hematological cancer
- pharmaceutical combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940079156 Proteasome inhibitor Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002489 hematologic effect Effects 0.000 title 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 229940124622 immune-modulator drug Drugs 0.000 title 1
- 239000003207 proteasome inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160127767A KR102002581B1 (en) | 2016-10-04 | 2016-10-04 | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer |
PCT/KR2017/011015 WO2018066946A1 (en) | 2016-10-04 | 2017-09-29 | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3522891A1 EP3522891A1 (en) | 2019-08-14 |
EP3522891A4 true EP3522891A4 (en) | 2020-04-15 |
Family
ID=61832016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17858740.8A Withdrawn EP3522891A4 (en) | 2016-10-04 | 2017-09-29 | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3522891A4 (en) |
JP (2) | JP2019529562A (en) |
KR (1) | KR102002581B1 (en) |
CN (1) | CN109789138A (en) |
AU (1) | AU2017338564B2 (en) |
BR (1) | BR112019006633A2 (en) |
CA (1) | CA3038019A1 (en) |
MX (1) | MX2019003907A (en) |
RU (1) | RU2721409C1 (en) |
WO (1) | WO2018066946A1 (en) |
ZA (1) | ZA201902340B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7415973B2 (en) | 2021-02-12 | 2024-01-17 | 信越化学工業株式会社 | Chemically amplified positive resist composition and resist pattern forming method |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1781639T3 (en) * | 2004-07-28 | 2012-07-31 | Janssen Pharmaceutica Nv | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
WO2007054719A2 (en) * | 2005-11-10 | 2007-05-18 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
MX2009002925A (en) * | 2006-09-15 | 2009-03-31 | Janssen Pharmaceutica Nv | Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors. |
WO2010085654A1 (en) * | 2009-01-23 | 2010-07-29 | Cancer Research Technology Limited | Hedgehog pathway inhibitors |
KR101168801B1 (en) * | 2009-03-27 | 2012-07-25 | 주식회사종근당 | Novel hydroxamate derivatives, method for the preparation thereof, and pharmaceutical composition containing the same |
WO2010124009A2 (en) * | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
US8610434B2 (en) | 2011-07-21 | 2013-12-17 | ColdEdge Technologies, Inc. | Cryogen-free cooling system for electron paramagnetic resonance system |
WO2013021032A1 (en) * | 2011-08-11 | 2013-02-14 | Janssen Pharmaceutica Nv | Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone |
KR102146848B1 (en) * | 2012-08-09 | 2020-08-21 | 셀진 코포레이션 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
CA2926808A1 (en) * | 2013-10-11 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
PT3080125T (en) * | 2013-12-12 | 2018-12-14 | Chong Kun Dang Pharmaceutical Corp | Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same |
-
2016
- 2016-10-04 KR KR1020160127767A patent/KR102002581B1/en active IP Right Grant
-
2017
- 2017-09-29 CN CN201780061019.9A patent/CN109789138A/en active Pending
- 2017-09-29 JP JP2019537733A patent/JP2019529562A/en active Pending
- 2017-09-29 AU AU2017338564A patent/AU2017338564B2/en not_active Ceased
- 2017-09-29 BR BR112019006633A patent/BR112019006633A2/en not_active Application Discontinuation
- 2017-09-29 RU RU2019108930A patent/RU2721409C1/en active
- 2017-09-29 WO PCT/KR2017/011015 patent/WO2018066946A1/en unknown
- 2017-09-29 MX MX2019003907A patent/MX2019003907A/en unknown
- 2017-09-29 EP EP17858740.8A patent/EP3522891A4/en not_active Withdrawn
- 2017-09-29 CA CA3038019A patent/CA3038019A1/en active Pending
-
2019
- 2019-04-12 ZA ZA2019/02340A patent/ZA201902340B/en unknown
-
2020
- 2020-10-28 JP JP2020180411A patent/JP2021020953A/en not_active Ceased
Non-Patent Citations (4)
Title |
---|
ANONYMOUS: "A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM) | Blood | American Society of Hematology", 13 November 2019 (2019-11-13), XP055674271, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/134/Supplement_1/1847/427755/A-Phase-1-OpenLabel-MultiCenter-Study-of> [retrieved on 20200306] * |
CHANSU LEE ET AL: "Abstract 1695: CKD-581, a novel histone deacetylase inhibitor, synergistically enhances Bortezomib cytotoxicity in multiple myeloma cells", EXPERIMENTAL AND MOLECULAR THERAPEUTICS, 30 September 2014 (2014-09-30), pages 1695 - 1695, XP055673884, DOI: 10.1158/1538-7445.AM2014-1695 * |
JONATHAN L. KAUFMAN ET AL: "Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy", CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA, vol. 13, no. 4, 17 June 2013 (2013-06-17), pages 370 - 376, XP055370013, ISSN: 2152-2650, DOI: 10.1016/j.clml.2013.03.016 * |
See also references of WO2018066946A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018066946A1 (en) | 2018-04-12 |
KR20180037507A (en) | 2018-04-12 |
AU2017338564A1 (en) | 2019-05-02 |
BR112019006633A2 (en) | 2019-07-02 |
CN109789138A (en) | 2019-05-21 |
AU2017338564B2 (en) | 2020-07-09 |
KR102002581B1 (en) | 2019-07-22 |
JP2021020953A (en) | 2021-02-18 |
JP2019529562A (en) | 2019-10-17 |
RU2721409C1 (en) | 2020-05-19 |
CA3038019A1 (en) | 2018-04-12 |
MX2019003907A (en) | 2019-08-05 |
EP3522891A1 (en) | 2019-08-14 |
ZA201902340B (en) | 2020-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3777888A4 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
EP3370748A4 (en) | Therapeutic microbiota for the treatment and/or prevention of food allergy | |
EP3533466A4 (en) | Pharmaceutical composition for cancer treatment and/or prevention | |
EP3076973A4 (en) | Combinations of histone deacetylase inhibitors and immunomodulatory drugs | |
EP3031826A4 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
EP3458159A4 (en) | Compositions and methods for the prevention and treatment of mitochondrial myopathies | |
EP3580560A4 (en) | Methods for the detection and treatment of lung cancer | |
EP3436002A4 (en) | Pharmaceutical combinations for the treatment of cancer | |
EP3694832A4 (en) | Extended release pharmaceutical formulation and methods of treatment | |
EP3592731A4 (en) | Inhibitors of malt1 and uses thereof | |
EP3448421A4 (en) | Methods and compositions for the prevention and treatment of surgical adhesions | |
EP3487492A4 (en) | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer | |
EP3615056A4 (en) | Methods and agents for the detection and treatment of cancer | |
EP3694523A4 (en) | Methods and substances for prevention and treatment of neurodegenerative diseases | |
EP3544612A4 (en) | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a cd38 inhibitor and methods of use thereof | |
EP3565549A4 (en) | Selective histone deacetylase inhibitors for the treatment of human disease | |
IL266486A (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
EP3532054A4 (en) | Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof | |
EP3468559A4 (en) | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors | |
EP3535275A4 (en) | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a bcl-2 inhibitor and methods of use thereof | |
EP3532065A4 (en) | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | |
EP3468540A4 (en) | Pharmaceutical compositions and methods for treatment of pain | |
EP3458444A4 (en) | Histone deacetylase 6 inhibitors and use thereof | |
EP3849992A4 (en) | Cd73 inhibitors and pharmaceutical uses thereof | |
EP3552612A4 (en) | Pharmaceutical preparation and medical instrument |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190314 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200318 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/416 20060101ALI20200312BHEP Ipc: A61K 31/454 20060101ALI20200312BHEP Ipc: A61P 35/00 20060101ALI20200312BHEP Ipc: A61K 31/56 20060101ALI20200312BHEP Ipc: A61K 31/573 20060101ALI20200312BHEP Ipc: A61K 38/00 20060101ALI20200312BHEP Ipc: A61K 31/496 20060101AFI20200312BHEP Ipc: A61K 31/69 20060101ALI20200312BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210216 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230203 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230614 |